바이오리액터 시장, 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Bioreactors Market was valued at approximately USD 10.4 billion in 2023 and is projected to expand at a CAGR of 11.8% from 2024 to 2032. A bioreactor serves as a controlled environment for cultivating organisms, ranging from bacteria and yeast to animal cells, or for conducting enzymatic or chemical reactions with these organisms. Industries, such as biotechnology, pharmaceuticals, and food production leverage bioreactors to produce a variety of products, including proteins, vaccines, enzymes, biofuels, and other bio-based materials.

The growing preference for single-use bioreactors valued for their reduced risk of cross-contamination, lower capital investments, and enhanced flexibility is promising to drive significant market growth. These advantages make single-use bioreactors especially appealing for small-scale and multiproduct manufacturing facilities.

The industry is divided into product type, cell, molecule, usage, material, size, end use , and region.

The market is segmented by product type into single-use and reusable categories. In 2023, the reusable segment led the market, generating a revenue of USD 7.7 billion. Reusable bioreactors stand out for their cost-effectiveness in large-scale production. Unlike their single-use counterparts, which are discarded after each run, reusable bioreactors can be sterilized and utilized multiple times. This capability translates to substantial long-term savings, a boon for industries like biopharmaceuticals that require large product batches.

Cell-based segmentation of the bioreactors market includes mammalian, bacterial, yeast, and other cells. The mammalian cells segment took the lead, boasting a valuation of USD 8.3 billion in 2023. Mammalian cells are particularly sensitive to environmental fluctuations, be it temperature, pH, oxygen levels, or nutrient availability. Bioreactors excel in providing a controlled setting, allowing meticulous regulation of these parameters to ensure optimal cell growth and productivity.

North American bioreactors market will hit USD 10.9 billion by 2032. Within this region, the U.S. led with a revenue of USD 3.8 billion in 2023. A key driving force is the robust presence of top-tier biopharmaceutical firms and research institutions in the U.S. These entities are pioneers in crafting innovative therapies, from monoclonal antibodies and vaccines to cutting-edge cell and gene therapies. Such a vibrant innovation landscape fuels a strong demand for advanced bioreactors, essential for both research and large-scale production.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing pharmaceutical and biotechnology industry
    • 3.2.1.2 Technological advancements in bioreactors
    • 3.2.1.3 Growing focus on orphan drug development
    • 3.2.1.4 Rising demand for personalized medicines
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Low capacity of single-use bioreactors
    • 3.2.2.2 Concerns regarding extractables and/or leachables
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Single-use
• 5.3 Reusable

Chapter 6 Market Estimates and Forecast, By Cell, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Mammalian cells
• 6.3 Bacterial cells
• 6.4 Yeast cells
• 6.5 Other cells

Chapter 7 Market Estimates and Forecast, By Molecule, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Monoclonal antibodies
• 7.3 Vaccines
• 7.4 Recombinant proteins
• 7.5 Stem cells
• 7.6 Gene therapy
• 7.7 Other molecules

Chapter 8 Market Estimates and Forecast, By Usage, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Developmental, pre-clinical and clinical
• 8.3 Commercial production

Chapter 9 Market Estimates and Forecast, By Material, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Stainless steel
• 9.3 Glass
• 9.4 Single-use

Chapter 10 Market Estimates and Forecast, By Size, 2018 - 2032 ($ Mn)

• 10.1 Less than 500 L
• 10.2 501-5,000 L
• 10.3 More than 5,000 L

Chapter 11 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 R and D organizations
• 11.3 Biopharma manufacturers
• 11.4 Contract manufacturing organizations (CMOs)

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Denmark
  • 12.3.7 Netherlands
  • 12.3.8 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 Japan
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 South Korea
  • 12.4.6 Singapore
  • 12.4.7 Rest of Asia Pacific
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Rest of Latin America
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 UAE
  • 12.6.3 Rest of Middle East and Africa

Chapter 13 Company Profiles

• 13.1 Altrad Group
• 13.2 BaiLun Biotechnology Co., Ltd
• 13.3 Bbi-biotech
• 13.4 Cellexus
• 13.5 CerCell A/S
• 13.6 Danaher Corporation
• 13.7 Donaldson Company, Inc
• 13.8 Eppendorf Group
• 13.9 Esco Micro Pte. Ltd.
• 13.10 GEA Group Aktiengesellschaft
• 13.11 Getinge AB
• 13.12 Merck KGaA
• 13.13 PBS Biotech, Inc.
• 13.14 Sartorius AG
• 13.15 Thermo Fisher Scientific Inc.